Risk Factors for Bleeding in a Patient Receiving Dasatinib Therapy for Chronic Myelogenous Leukemia (CML)

Description

Quintas-Cardama et al identified risk factors associated with dasatinib therapy to a patient with chronic myelogenous leukemia (CML). Dasatinib is a tyrosine kinase inhibitor that is used when the patient is resistant to or intolerant of imatinib mesylate. The authors are from the University of Texas M.D. Anderson Cancer Center in Houston.

Risk factors for bleeding during dasatinib therapy:

(1) acute or blast phase of CML

(2) thrombocytopenia

(3) dose of dasatinib >= 140 mg/day

where:

• A twice daily dosing regimen tended to be increase the risk but did not reach statistical significance.

• Coagulation tests often are normal in patients with bleeding.

• Dasatinib causes platelet dysfunction.

Most bleeding occurred in the gastrointestinal tract and was relatively mild.

If bleeding is detected then therapy with dasatinib should be interrupted.

Additional risk factors for bleeding:

(1) exposure to other drugs causing platelet dysfunction

(2) presence of an ulcer, diverticulum or other lesion

(3) coagulopathy

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10